NAFTIDROFURYL USE IN MODERATE VASCULAR COGNITIVE DISORDERS

Prevention of progression to moderate vascular cognitive disorders (MVCD) in dementia is based on medicinal and nonmedicinal correction of major cardiovascular risk factors, at the same time antidementia, vasoactive and nootropic drugs efficiency is not proven. The own experience of use in 30 patien...

Full description

Saved in:
Bibliographic Details
Published inMedicinskij sovet no. 1S; pp. 22 - 26
Main Authors V. A. Parfenov, A. B. Lokshina, D. A. Grishina, Y. A. Starchina, O. V. Kosivtsova
Format Journal Article
LanguageRussian
Published Remedium Group LLC 01.12.2017
Subjects
chronic cerebral ischemia
discirculatory encephalopathy
duzofarm
moderate cognitive disorders
naftidrofuryl
vascular cognitive disorder
Online AccessGet full text

Cover

More Information
Summary:Prevention of progression to moderate vascular cognitive disorders (MVCD) in dementia is based on medicinal and nonmedicinal correction of major cardiovascular risk factors, at the same time antidementia, vasoactive and nootropic drugs efficiency is not proven. The own experience of use in 30 patients (22 women and 8 men) with MVCD in age from 46 to 75 years (mean age 67,1 ± 6.6 years) of Naftidrofuryl (Duzofarm) at a dose of 100 mg three times a day for 30 days is provided. After a month of treatment a significant improvement of cognitive function by the Montreal scale assessment of mental functions, the alpha-numeric coding test, and emotional state test is established as measured by the hospital scale of anxiety and depression. Good tolerability, absence of significant side effects when using Naftidrofuryl for MVCD are observed. Longer placebo-controlled studies of the effectiveness of Naftidrofuryl in patients with MVCD are needed.
ISSN:2079-701X
2658-5790
DOI:10.21518/2079-701X-2017-0-22-26